Zhan Hongliang, Hong Yiyan, Zhang Longying, Huang Kunzhai, Zheng Miaomiao, Zhang Fuxing
Department of General Surgery, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
The School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
Gland Surg. 2024 Sep 30;13(9):1619-1627. doi: 10.21037/gs-24-273. Epub 2024 Sep 27.
The 8th edition of the American Joint Committee on Cancer (AJCC)'s T-stage for differentiated thyroid cancer (DTC) removes minimal extrathyroidal extension (mETE), while ignoring the risk of mETE would lead to overtreatment or inadequate treatment. The aim of this study was to investigate the impact of location and size of mETE on lymph node metastasis in papillary thyroid cancer (PTC).
A retrospective analysis of 267 patients who underwent unilateral radical surgery for PTC was conducted. According to the postoperative pathology, they were divided into mETE group (121 patients) and non-mETE group (146 patients). The number of lymph nodes dissected and the number of lymph nodes metastasized were compared between the two groups. The linear regression analysis and the receiver operating characteristic (ROC) curves were performed to evaluate the impact of the locations and sizes on lymph node metastasis.
There was no significant difference in the number of lymph node dissected between the mETE group and the non-mETE group. The tumor located at the upper part and the size <1.0 cm in mETE group showed a higher number of lymph node metastasis (0.78±0.88 0.25±0.45, P=0.03). Meanwhile, in the mETE group, the number of patients with lymph node metastasis was higher than that in the non-mETE group. Further subgroup analysis revealed that for PTC patients with tumors at the upper part and size <1.0 cm, the number of those with lymph node metastasis in the mETE group was also greater than that in the non-mETE group. Furthermore, the Spearman correlation analysis showed a positive correlation between tumors located at the upper part with a size <1.0 cm and lymph node metastasis rate (R=0.647, P=0.004). Additionally, if the upper part tumor was within 1 cm, the tumor's size was able to identify the lymph node metastasis, with the optimal cut-off point of 0.45 cm (Youden index =0.650).
When tumors combine with mETE, the probability of lymph node metastasis increases in tumors located at the upper part with a size <1.0 cm. Especially, when the upper part tumor is within 1 cm, the tumors of size ≥0.45 cm are more likely to have lymph node metastasis.
美国癌症联合委员会(AJCC)第8版分化型甲状腺癌(DTC)的T分期去除了微小甲状腺外侵犯(mETE),而忽视mETE的风险会导致过度治疗或治疗不足。本研究旨在探讨mETE的位置和大小对甲状腺乳头状癌(PTC)淋巴结转移的影响。
对267例行单侧PTC根治性手术的患者进行回顾性分析。根据术后病理,将他们分为mETE组(121例)和非mETE组(146例)。比较两组清扫淋巴结数量和转移淋巴结数量。进行线性回归分析和受试者工作特征(ROC)曲线分析,以评估位置和大小对淋巴结转移的影响。
mETE组和非mETE组清扫淋巴结数量无显著差异。mETE组位于上部且大小<1.0 cm的肿瘤淋巴结转移数量较多(0.78±0.88对0.25±0.45,P=0.03)。同时,mETE组淋巴结转移患者数量高于非mETE组。进一步亚组分析显示,对于肿瘤位于上部且大小<1.0 cm的PTC患者,mETE组淋巴结转移患者数量也多于非mETE组。此外,Spearman相关性分析显示,位于上部且大小<1.0 cm的肿瘤与淋巴结转移率呈正相关(R=0.647,P=0.004)。另外,如果上部肿瘤在1 cm以内,肿瘤大小能够识别淋巴结转移,最佳截断点为0.45 cm(约登指数=0.650)。
当肿瘤合并mETE时,位于上部且大小<1.0 cm的肿瘤发生淋巴结转移的概率增加。特别是,当上部肿瘤在1 cm以内时,大小≥0.45 cm的肿瘤更有可能发生淋巴结转移。